Addressing Unmet Needs in Advanced Endometrial Cancer: The Latest Advances for the Oncology Nurse

Chattanooga, TN US
February 23, 2023

Strategically designed to foster an understanding of both the disease state complexity and far-reaching disparity intrinsic to endometrial cancer, this educational session will begin with an appraisal of the utility and importance of biomarker testing in advanced endometrial cancer, and the latest data related to immune checkpoint inhibitor treatments in advanced endometrial cancer. The role of the oncology nurse in mitigating and managing toxicities with these agents will also be explored. Finally, expert faculty will then guide attendees through a real-world interactive case-based discussion centered on how the oncology nurse can provision patient-centric care that is both efficacious and equitable through the incorporation of novel immune checkpoint inhibitor therapies and the adoption of renewed perspectives.

Target Audience

This activity is designed to meet the educational needs of oncology nurses and nurse practitioners attending local ONS Chapter Meetings across the U.S.

Learning Objectives

  • Identify the predictive biomarkers that allow for tailored treatment options for patients with endometrial cancer, exploring the role of the oncology nurse in molecular testing.
  • Appraise recent clinical evidence on the safety and efficacy of immune checkpoint inhibitor monotherapy and combinatorial regimens for the treatment of advanced or recurrent endometrial cancer.
  • Analyze the unique toxicities of immune checkpoint inhibitors for endometrial cancer and important considerations for both monitoring and managing adverse events.
  • Use a case-based approach to recognize and address socioeconomic and racial disparities affecting health outcomes in endometrial cancer patients and how the oncology nurse can provide patient-centric care that is both efficacious and equitable.

Presented by Creative Educational Concepts, LLC.

Supported through independent educational grants from GlaxoSmithKline, Eisai, and Merck.

Additional Information

PDF icon General Information940.22 KB
PDF icon Handout and References2.49 MB
Course summary
Available credit: 
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
Course expires: 
Event starts: 
02/23/2023 - 6:00pm EST
Event ends: 
02/23/2023 - 7:00pm EST

5 min     Welcome and Introductions/Pre-test

10 min   Tailoring Treatment for Patients with Endometrial Cancer: Exploring the Role of Predictive Biomarkers

15 min   Analyzing the Latest Data on Immune Checkpoint Inhibitors for Advanced Endometrial Cancer: What Does the Data Tell


20 min   Advanced Endometrial Cancer Clinical Case Review: Bridging Gaps in Care Using Immune Checkpoint Inhibitors and

              the Role of the Oncology Nurse

10 min   Conversations with the Experts/Audience Q&A/Post-test

Chattanooga ONS
Public House Chattanooga
1110 Market Street, Suite 101
Chattanooga, TN 37402
United States

Sirithepphavanh S. Oliver, NP
Nurse Practitioner Obstetrics & Gynecology
Hospital of University of Pennsylvania
Philadelphia, PA



It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Sirithepphavanh S. Oliver, NP—has disclosed that she is on the Speakers Bureau for GlaxoSmithKline.

Carina L. DeCroes, APRN, CNP–has no relevant financial relationships to disclose in relation to the content of this activity.
Sirithepphavanh S. Oliver, NP—has disclosed that she is on the Speakers Bureau for GlaxoSmithKline.
Mary B. Welch, MS, FNP, AOCN—has no relevant financial relationships to disclose in relation to the content of this activity.

Peer Reviewer:
Julie Mary George, NP–has no relevant financial relationships to disclose in relation to the content of this activity.

CEC Staff:
Tina L. Trieu, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Nursing (ANCC)
This activity is designated for 1.0 contact hour.

ONCC/ILNA Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. OCN®, AOCNP®, CBCN®, BMTCN® and CPHON® nurses may apply 1.0 point in Care Continuum, Oncology Nursing Practice, Professional Practice/Performance, and Treatment categories. 

Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. 

Available Credit

  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.